National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the Patent Applications listed in the Summary Information section of this notice to Apexx Oncology, Inc., located in New York, NY.
Document
Prospective Grant of Exclusive Patent License: Mutant IDH1 Inhibitors Useful for Treating Cancer
National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
83 FR 29562
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Prospective Grant of Exclusive Patent License: Mutant IDH1 Inhibitors Useful for Treating Cancer,” thefederalregister.org (June 25, 2018), https://thefederalregister.org/documents/2018-13486/prospective-grant-of-exclusive-patent-license-mutant-idh1-inhibitors-useful-for-treating-cancer.